



Supplementary Figure 1: Treatment with *P. histicola* alone, IFN β alone, and combination of *P.histicola* plus IFN β did not caused pathology in the upper gut. HLA-DR3.DQ8 transgenic mice were immunized with PLP₉₁₋₁₁₀ and were either treated with *P. histicola*, IFN β , and combination of *P. histicola* plus IFN β or medium starting at 7 days post-immunization for a total of 7 doses. Small intestinal tissue of Media, *P. histicola*, *P. histicola* and IFN β combination and IFN β treated mice were stained with hematoxylin and eosin.







Brain Iba1

Spinal Cord Iba1

Media




P. his

P. his
+
IFN β IFN β 


Supplementary Figure 2. *P. histicola* alone, IFN β alone, or the combination of *P. histicola* and IFN β resulted in decreased microglial activation in the brain and spinal cord of mice with EAE. Ionized calcium-binding adaptor protein-1 (Iba-1) staining of the brain (left three columns) and spinal cord sections (right three columns) from mice induced with EAE that received treatment with either *P. histicola* alone, IFN β alone, the combination of both treatments, or media. The data presented at 4X resolution.

Brain GFAP

Spinal Cord GFAP




Supplementary Figure 3. *P. histicola* alone, IFN β alone, or the combination of *P. histicola* and IFN β treatments reduced astrocytes activation in the brain and spinal cord of mice with EAE. A) Staining glial fibrillary acidic protein (GFAP) of the brain (left three columns) and spinal cord sections (right three columns) from mice induced with EAE that received treatment with either *P. histicola* alone, IFN β alone, the combination with IFN β , or media only. The data presented at 4X resolution




Supplementary Figure 4. Treatment with *P. histicola* alone, IFN β alone, or the combination of *P. histicola* and IFN β reduced GFAP and Iba1 protein expression in spinal cord of mice with EAE. The spinal cord's tissues from mice with EAE were collected and lysed in radioimmunoprecipitation assay (RIPA) buffer. Protein concentrations were determined using NanoDrop Spectrophotometer. 200 μ g proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Expression of GFAP and Iba1 were analyzed using anti-GFAP and anti-Iba1 antibody respectively. Representative protein expression of GFAP and Iba1 of the spinal cord tissue from mice induced with EAE that received treatment with either *P. histicola* alone, IFN β alone, the combination with IFN β , or media only.

A)




B)




Supplementary Figure 5. Pre-treatment with *P. histicola* alone or in combination with IFN β increases CD4⁺IL10⁺ T cells in the gut-associated lymphoid tissue (GALT). **A)** Naïve mice were treated with IFN β (7 doses), *P. histicola* (7 doses), or a combination of both (with treatment administered on alternate days for a total of 14 doses). Gut-associated lymphoid cells were isolated from treated and the control group of mice and stained with CD45, CD4, and IL10 antibodies. Frequency of CD4⁺IL10⁺ T cells from mice treated as mentioned. **B)** Quantification of the number of CD4⁺IL10⁺ regulatory T cells in mice treated as in A. Error bars are presented as the standard error of the mean. The *p*-value determined by the Mann-Whitney unpaired U test for comparing each group to media.


A)




B)



Supplementary Figure 6: Criteria for setting positive gates for specific fluorochrome FoxP3 (A) and a representative gating strategy for different cell populations isolated from gut-associated lymphoid tissue (B).



Supplementary Figure 7: Representative gating strategy for different population (IL17+, IFN γ +, and GM-CSF⁺ CD4 T Cells) isolated from gut-associated lymphoid tissue.



Supplementary Figure 8: Representative gating strategy for different population (IL17⁺ and IFN γ ⁺ CD4 T Cells) isolated from CNS.